tapebrief
ZBH · Q3 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

ZBH · Q4 2025 Earnings

Zimmer Biomet

Reported February 10, 2026

30-second summary

Zimmer Biomet closed FY2025 inside every guided range — organic CC growth 3.9% (guide 3.5–4.0%), adjusted EPS $8.20 (guide $8.10–$8.30), FCF $1.172B (guide $1.0–1.2B) — and used the Q4 print to issue an FY2026 organic constant-currency growth guide of 1.0–3.0% with adjusted EPS of $8.30–$8.45 (+1–2% YoY). The midpoint of 2.0% organic growth sits ~190bps below FY2025 actual and well below the prior watch-list threshold of 4% that would have signaled "discipline pledge intact." Management attributed the deceleration to a U.S. Salesforce transition framed as "the final core initiative in a transformation," ending a five-year mid-single-digit-or-above streak with a year of self-inflicted disruption.

Headline numbers

EPS

Q4 FY2025

$2.42

Revenue

Q4 FY2025

$2.24B

+10.9% YoY

Operating margin

Q4 FY2025

6.9%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$2.24B+10.9%$2.00B+12.1%
EPS$2.42—$1.90+27.4%
Operating margin6.9%—17.5%-1061bps

Guidance

Company beat or met all FY2025 guidance on EPS, revenue, organic growth, and free cash flow; issued FY2026 guidance showing significant deceleration in organic and reported revenue growth (1–3% organic vs 3.9% FY2025 actual) with modest EPS growth of 1–2%, citing Salesforce transition risk and international market headwinds.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Adjusted Diluted EPSFY2025$8.10 - $8.30$8.20in-lineMet
Reported Revenue ChangeFY20256.7% - 7.7%7.2%in-lineMet
Organic Constant Currency Revenue ChangeFY20253.5% - 4.0%3.9%in-lineMet
Free Cash FlowFY2025$1.0 billion to $1.2 billion$1.172 billionin-lineMet

New guidance

MetricPeriodGuideYoY
Adjusted Diluted EPSFY2026$8.30 - $8.45+1.2% to +2.0%
Organic Constant Currency Revenue ChangeFY20261.0% - 3.0%—
Reported Revenue ChangeFY20262.5% - 4.5%—
Constant Currency Revenue ChangeFY20262.0% - 4.0%—
Free Cash Flow GrowthFY20268% - 10%—

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
Knees$0.911B+8.6%
Hips$0.555B+6.8%
S.E.T.$0.588B+20.1%
Technology & Data, Bone Cement and Surgical$0.19B+8.7%
S.E.T. Segment Reported Growth (Q4)20.1%—
S.E.T. Segment Organic Constant Currency Growth (Q4)2.9%—

Other KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
United States$1.313B+11.1%
International$0.931B+10.6%
Organic Constant Currency Revenue Growth (Q4)5.4%—
Organic Constant Currency Revenue Growth (FY2025)3.9%—
Adjusted Diluted EPS (FY2025)$8.20—
Adjusted Diluted EPS Growth (FY2025)2.5%—
Free Cash Flow (FY2025)$1.172 billion—
Operating Cash Flow (FY2025)$1.697 billion—

Management tone

Q2 "very high confidence" in H2 → Q3 "measured guidance" pledge → Q4 1–3% organic guide and Salesforce overhaul → 2026 as a transformation year.

Three quarters ago CEO Ivan Tornos staked credibility on a six-handle Q3 organic print and second-half acceleration. One quarter ago he walked it back and pre-committed to a "measured" 2026 framework. This quarter he delivered a 2026 organic CC guide whose midpoint (2.0%) sits below even the watch-list threshold that would have signaled the discipline pledge was holding — and named the gating reason: "The evolution of the U.S. Salesforce represents the final core initiative in a transformation. And while it might create some short-term disruption across pockets of an organization, it is by far the most crucial step." The Q3 reset has now translated into a number, and the number is worse than the reset implied.

Last quarter international weakness was the source of the FY2025 guide cut, framed as concentrated in non-core distributor channels that would be stripped from forward commentary. This quarter the source of slowdown shifted internal: management is voluntarily disrupting the U.S. sales channel — the largest revenue line on the page — to convert 1099 and non-dedicated reps to a "100% dedicated" model. The phrase "This is not a time to add more complexity...This is the time to be nimble and laser-focused on getting those three integrations right" signals M&A is paused, which is itself a tonal break from the three-acquisitions-in-twelve-months posture of 2024–2025.

The hedging-language density rose materially. The CEO's statement that "if we don't do the job that I expect we're going to do, then we may move towards the lower range of that guidance" is unusual pre-commitment to the floor of a guidance range on the day it is issued — and the FY2026 guide "contemplates" end-market growth in line with 2025 rather than the prior framing of confidence in market conditions. Verb choice has moved from "expect" to "contemplates" across the prepared remarks.

The Paragon 28 narrative shifted from acquisition story to integration accountability. Tornos's explicit commitment "that we're going to grow this business double digit in 2026, early in 2026" — paired with the admission that 2025 contribution was "slightly behind what we anticipated" — converts a multi-quarter soft data point into a falsifiable 2026 milestone.

The gross-margin commentary from CFO Suky Upadhyay is the cleanest tell on FY2026 mechanics: 70–71% gross margin versus Q4 FY2025's 72.4% (~140bps compression) attributed primarily to lost volume leverage. This is a margin story, not a mix story, and it implies that the EPS guide is dependent on cost discipline rather than operational leverage — a configuration the company has not been in for several years.

Recurring themes management leaned on this quarter:

U.S. Salesforce transformation as critical competitive necessity despite near-term disruptionNew product portfolio strength (Magnificent 7, mBoss, iodine-coated devices, Oxford Partial) driving momentum but requiring dedicated channel to monetizeIntegration complexity from three acquisitions in 12 months requiring focused executionInternational markets described as 'fragile' with inconsistent quarter-to-quarter performanceASC channel penetration expansion as growth opportunity with dedicated resources addedFree cash flow generation and shareholder returns prioritized over near-term growth

Risks management surfaced:

U.S. Salesforce transition disruption risk in 2026 affecting growth trajectoryInternational market volatility and inconsistent performance ('fragile business now for a couple of quarters')Gross margin compression from lower organic growth rates reducing P&L leverageParagon 28 integration execution risk to achieve double-digit growth commitmentFoot and ankle market softness in 2025 with modest Paragon contribution to date

Answers to last quarter's watch list

The 2026 guide framework. Organic CC midpoint of 2.0% sits below the 4% threshold that would have confirmed "measured discipline" and well below the 5% threshold that would have flagged rhetorical commitment. The reset is real — and arguably more aggressive than the August pledge implied. Management explicitly framed the year as transformation-driven rather than market-driven, with the Salesforce transition named as the largest swing factor. Status: Resolved negatively.
Q4 FY2025 organic CC inside the new 3.5–4.0% range. Q4 organic CC printed 5.4% — well above the implied Q4 deceleration the FY range required, and the cleanest beat of the year. FY organic CC of 3.9% landed in the upper half of the narrowed guide. The August damage was not compounded; the quarter itself was the strongest of the year. Status: Resolved positively.
U.S. revision-market commentary. Not explicitly addressed in the press-release extraction; with no live transcript available, the language has not been confirmed either way. Hips at +6.8% reported in Q4 (vs. +5.1% in Q3 reported) suggests no material deterioration. Status: Continue monitoring.
Hips trajectory. Q4 Hips printed $555M, +6.8% reported, versus Q3's $506M at +5.1% reported — a clean sequential acceleration on a reported basis. The revision-market drag flagged in Q3 did not visibly worsen in Q4. Status: Resolved positively.
International ex-distributor underlying growth. International printed +10.6% reported in Q4 versus +8.5% in Q3 reported, but management's repeated use of "fragile" and the new "evolution of international go-to-market models" risk language in the 2026 guide commentary suggests the underlying organic figure has not stabilized — only the FX tailwind and selective wins have masked it. Status: Continue monitoring.
Free cash flow conversion. FY FCF landed at $1.172B, near the top of the $1.0–1.2B guide. The Q4 implied figure was credible and delivered. The FY2026 guide of 8–10% FCF growth implies $1.27–1.29B, which would be the fourth consecutive year of meaningful FCF growth despite revenue deceleration. Status: Resolved positively.

What to watch into next quarter

Q1 FY2026 organic CC print versus the 1–3% FY range. Management guided "growth to be roughly consistent throughout the year, plus or minus from quarter to quarter" — so a Q1 print materially below 1% would imply the Salesforce disruption is front-loaded and back-half recovery is the bet. A print above 3% would suggest the FY guide is conservatively set against a smoother transition.

U.S. revenue growth specifically. The Salesforce transition is U.S.-only; U.S. revenue grew +11.1% reported in Q4. Watch whether U.S. organic decelerates sharply in Q1 — that is the cleanest measurement of transition friction.

Paragon 28 organic growth trajectory toward the double-digit 2026 commitment. S.E.T. organic CC was only 2.9% in Q4. Watch whether Paragon's contribution to S.E.T. inflects upward in early 2026 reporting; the public commitment makes this a falsifiable test.

Gross margin print in Q1. Management guided 70–71% for FY2026 versus 72.4% in Q4 FY2025. A Q1 print below 70% would suggest the volume-leverage drag is worse than modeled and put the $8.30–8.45 EPS floor at risk.

Any M&A commentary. Management explicitly paused M&A this quarter ("not a time to add more complexity"). Any reversal would signal either integration milestones are landing faster than expected or that the organic trajectory needs supplementing.

Free cash flow Q1 pace. The 8–10% FCF growth guide implies $1.27–1.29B; Q1 FCF historically is the weakest quarter, so watch the absolute number against prior-year Q1 to gauge whether the FY guide is tracking.

Sources

  1. Zimmer Biomet Q4 FY2025 Press Release (SEC EX-99.1): https://www.sec.gov/Archives/edgar/data/1136869/000119312526043620/zbh-ex99_1.htm
  2. Q4 FY2025 prepared-remarks commentary referenced via extraction; live transcript unavailable at time of writing.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.